IL-13 Surpass ELISA Kit: Unveiling Core Roles and Therapeutic Potential in Asthma and Allergic Diseases
11 Mar 2026
Concept: IL-13 – A Pivotal Mediator of Type 2 Immunity and Allergic Inflammation
Interleukin-13 (IL-13) is a multifunctional pleiotropic cytokine primarily secreted by type 2 helper T cells (Th2), with additional cellular sources including CD8+ T cells, mast cells, basophils, eosinophils, and natural killer cells. Sharing overlapping gene sequences and receptor signaling pathways with IL-4—both utilizing the IL-4Rα/IL-13Rα1 receptor complex—IL-13 exhibits distinct and irreplaceable biological effects that position it as a central regulator of type 2 immune responses and tissue homeostasis.
The core biological functions of IL-13 span immune regulation, inflammation, and tissue remodeling:
- B cell modulation: Induces the expression of CD23 and MHC class II molecules on B cells, while promoting IgE class switching and synthesis—key drivers of allergic humoral immune responses.
- Monocyte/macrophage regulation: Facilitates monocyte fusion into foreign body-type multinucleated giant cells, upregulates surface CD23 and mannose receptor expression, and inhibits lipopolysaccharide (LPS)-activated monocytes/macrophages from producing pro-inflammatory cytokines (e.g., IL-1, IL-6, IL-8), balancing anti-inflammatory effects with tissue remodeling.
- Endothelial cell activation: Selectively induces vascular cell adhesion molecule-1 (VCAM-1) expression on vascular endothelial cells, promoting the adhesion and migration of inflammatory cells such as eosinophils to sites of inflammation.
Dysregulated IL-13 signaling is closely linked to the pathogenesis of allergic diseases, particularly asthma, where it drives chronic airway inflammation, hyperresponsiveness, and mucus hypersecretion—making it a critical target for research and therapeutic development.
Research Frontiers of IL-13 in Asthma and Allergic Diseases
The field of IL-13 research is advancing rapidly, with cutting-edge investigations focusing on unraveling its complex roles in disease pathogenesis, optimizing targeted therapies, and expanding diagnostic applications. A core research frontier is the precise dissection of IL-13’s tissue-specific effects in asthma—specifically, how it acts directly on airway epithelial cells, smooth muscle cells, and fibroblasts to induce pathological changes independent of lymphocyte involvement. Key areas of exploration include IL-13’s role in mucus hypersecretion (via goblet cell hyperplasia and MUC5AC production), airway hyperresponsiveness (by altering smooth muscle contractility), and airway remodeling (through TGF-β induction and extracellular matrix deposition via the alternative IL-13Rα2 receptor).
Another critical research direction is the development and refinement of IL-13-targeted therapeutics. Building on the success of early biologics, current efforts focus on three main strategies: anti-IL-13 monoclonal antibodies that neutralize free IL-13, soluble IL-13 receptor fusion proteins (decoy receptors) that competitively bind circulating IL-13, and receptor-targeted drugs (e.g., anti-IL-4Rα antibodies) that simultaneously block IL-4 and IL-13 signaling. Clinical trials for moderate-to-severe asthma have demonstrated promising results, with these therapies improving lung function and reducing acute exacerbations—particularly in patients with type 2 inflammation phenotypes.
Emerging research also explores IL-13’s role in other allergic diseases (e.g., atopic dermatitis, allergic rhinitis) and fibrotic conditions (e.g., idiopathic pulmonary fibrosis), expanding its therapeutic potential beyond asthma. The IL-13 Surpass ELISA Kit is central to these advances, enabling accurate quantification of IL-13 in preclinical models and clinical samples to support mechanism studies, drug development, and patient stratification.
Research Significance of IL-13 in Asthma and Allergic Disease Studies
Unraveling the role of IL-13 in asthma and allergic diseases holds profound scientific, clinical, and translational significance for immunology, pulmonology, and precision medicine.
In basic research, IL-13 studies provide critical insights into the molecular mechanisms of type 2 immune responses and their dysregulation in allergic diseases. By elucidating how IL-13 interacts with its receptors to drive tissue-specific pathology, researchers gain a deeper understanding of immune homeostasis and the breakdown of this balance in disease. This knowledge not only advances our comprehension of asthma but also informs the study of other IL-13-driven conditions, such as fibrosis and parasitic infections.
Translationally, IL-13-targeted therapies have revolutionized the treatment of moderate-to-severe asthma, offering new options for patients poorly controlled by traditional steroids and bronchodilators. These biologics address the root cause of type 2 inflammation, improving clinical outcomes and reducing reliance on systemic corticosteroids—minimizing long-term side effects. Research on IL-13 continues to drive the development of more precise and effective therapeutics, including combination therapies that target multiple cytokines or pathways for synergistic effects.
Clinically, IL-13 serves as a valuable biomarker for identifying patients with type 2 inflammation phenotypes, enabling personalized treatment strategies. By quantifying IL-13 levels in serum or bronchoalveolar lavage fluid (BALF), clinicians can predict response to IL-13-targeted therapies, stratify patients, and monitor treatment efficacy—moving toward precision medicine in asthma management.
Mechanisms, Research Methods and Product Applications
Core Mechanisms of IL-13 in Asthma Pathogenesis
IL-13 drives asthma pathogenesis through a multifaceted mechanism centered on type 2 immune activation and tissue remodeling:
- Type 2 immune amplification: IL-13 promotes the differentiation and activation of Th2 cells, eosinophils, and mast cells, amplifying the production of other pro-allergic cytokines (e.g., IL-4, IL-5) and IgE, creating a self-perpetuating inflammatory loop.
- Airway epithelial cell dysfunction: Directly stimulates airway epithelial cells to secrete chemokines (e.g., eotaxin) that recruit eosinophils, while inducing goblet cell hyperplasia and MUC5AC production—leading to mucus hypersecretion and airway obstruction.
- Smooth muscle hyperresponsiveness: Alters the contractile properties of airway smooth muscle cells, increasing their sensitivity to environmental stimuli and contributing to bronchoconstriction.
- Airway remodeling: Binds to IL-13Rα2 on fibroblasts, inducing TGF-β secretion and promoting fibroblast activation, collagen deposition, and airway wall thickening—resulting in irreversible structural changes and progressive lung function decline.
Key Research Methods for IL-13 Studies
Investigating IL-13’s role in asthma and allergic diseases relies on specialized tools and techniques to quantify IL-13 levels, analyze signaling pathways, and evaluate therapeutic efficacy. Core research methods include:
- Quantitative IL-13 detection: Enzyme-Linked Immunosorbent Assay (ELISA) is the gold standard for measuring IL-13 concentrations in biological samples (serum, plasma, BALF, cell culture supernatants, tissue homogenates). The IL-13 Surpass ELISA Kit offers high sensitivity and specificity, enabling accurate quantification across a broad dynamic range—from baseline physiological levels to pathologically elevated concentrations in disease.
- Cellular and molecular signaling analysis: Western Blot, qPCR, and immunofluorescence are used to study IL-13-mediated activation of JAK/STAT6, MAPK, and TGF-β pathways, as well as the expression of downstream target genes (e.g., MUC5AC, VCAM-1).
- Preclinical disease models: Animal models of allergic asthma (e.g., ovalbumin-induced asthma) are used to evaluate IL-13’s pathological role and test the efficacy of novel therapeutics, monitoring IL-13 levels and downstream inflammatory endpoints.
- Clinical sample analysis: IL-13 levels in patient samples are correlated with disease activity, severity, and treatment response, supporting biomarker development and personalized medicine approaches.
- Immune cell functional assays: In vitro stimulation of T cells, mast cells, or eosinophils with allergens or specific stimulants, followed by IL-13 detection, to assess regulatory effects of genes, drugs, or cell subsets on IL-13 production.
ANT BIO PTE. LTD.’s IL-13 Surpass ELISA Kit: Empowering Disease Research and Therapy
ANT BIO PTE. LTD. addresses the critical need for high-quality IL-13 detection tools through its Absin sub-brand (specializing in general reagents and kits), offering the Human IL-13 Enhanced ELISA PairSet Kit (Catalog No.: S0H2002). This meticulously designed kit provides researchers with rigorously validated capture and detection antibody pairs, enabling the development of high-performance sandwich ELISA systems for accurate and reliable quantification of human IL-13. It is an indispensable tool for asthma research, allergic disease studies, and drug development.
Core Advantages of ANT BIO PTE. LTD.’s Human IL-13 Enhanced ELISA PairSet Kit (S0H2002)
| Core Advantages | Detailed Product Characteristics |
|---|---|
| Exceptional Specificity and Minimal Cross-Reactivity | Equipped with high-affinity, highly specific capture and biotin-labeled detection antibody pairs. Rigorous cross-reactivity testing confirms minimal interference from other Th2 cytokines (e.g., IL-4, IL-5), ensuring accurate IL-13 quantification even in complex biological samples with mixed cytokine profiles. |
| High Sensitivity and Broad Dynamic Range | Enables pg/mL-level detection sensitivity, allowing for the quantification of low baseline IL-13 levels. The broad quantitative range accurately covers IL-13 concentrations from physiological baseline to pathologically elevated levels in asthma and allergic diseases, meeting the diverse needs of basic research, preclinical studies, and clinical sample analysis. |
| Flexible Customization and Cost-Effectiveness | Provided as a reagent set, allowing researchers to optimize experimental protocols (coating conditions, blocking reagents, incubation times) and calibrate standard curves based on specific sample types (serum, plasma, BALF, cell supernatants) and detection platforms. This flexibility, combined with its raw material format, offers a cost-effective solution for long-term, large-scale research projects and diagnostic reagent development. |
| Reliable Performance and Batch Consistency | Manufactured under stringent quality control standards, ensuring consistent performance across batches. Each kit undergoes rigorous validation for sensitivity, specificity, reproducibility, and stability, providing researchers with reliable, actionable data that supports robust scientific conclusions. |
Key Application Scenarios for S0H2002 Human IL-13 Enhanced ELISA PairSet Kit
- Asthma and Allergic Disease Research: Quantify IL-13 levels in patient serum, BALF, or tissue samples to assess disease activity, study pathogenic mechanisms, and explore IL-13 as a prognostic or therapeutic response biomarker.
- Type 2 Immune Response Evaluation: Measure IL-13 secretion from T cells, eosinophils, or mast cells stimulated by allergens (e.g., dust mites, pollen) or parasites to assess the intensity of type 2 immune responses.
- Drug Screening and Preclinical Development: Serve as a core pharmacodynamic indicator for high-throughput screening and evaluation of IL-13-targeted therapeutics (e.g., dupilumab, tralokinumab); monitor in vitro and in vivo inhibitory effects to support drug optimization and efficacy assessment.
- Fibrosis and Parasitic Infection Studies: Analyze IL-13 levels in models of idiopathic pulmonary fibrosis, liver fibrosis, or parasitic infections to explore its role in disease progression and therapeutic potential.
- Clinical Trial Monitoring: Monitor pre- and post-treatment IL-13 level changes in patient samples during clinical trials of IL-13-targeted therapies, informing patient stratification and outcome prediction.
Related Product List
| Catalog Number | Product Name | Core Features | Key Applications | Sub-brand | Stock Status |
|---|---|---|---|---|---|
| S0H2002 | Human IL-13 Enhanced ELISA PairSet Kit | High sensitivity (pg/mL level); broad dynamic range; minimal cross-reactivity; antibody pair format | Asthma research, allergic disease studies, drug screening | Absin | In Stock |
| - | Anti-Human IL-13 Recombinant Monoclonal Antibody | High specificity; validated for WB/IF/FCM | IL-13 expression analysis, immune cell sorting | Starter | In Stock |
| - | Human IL-4 ELISA Kit | High sensitivity; quantitative; suitable for serum/plasma/cell supernatants | Type 2 immune response profiling, therapeutic efficacy evaluation | Absin | In Stock |
| - | Recombinant Human IL-13 Protein (His Tag) | HEK293-expressed; high purity; bioactive | ELISA standard curve calibration, antibody validation | UA | In Stock |
| - | Anti-Human IL-4Rα Recombinant mAb | High specificity; validated for WB/IHC | IL-13/IL-4 signaling pathway research, receptor expression analysis | Starter | In Stock |
| - | Eotaxin ELISA Kit | High sensitivity; quantitative; suitable for BALF/serum | Eosinophil recruitment monitoring, asthma inflammation assessment | Absin | In Stock |
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
